A Two-part Study To Assess the Safety and Preliminary Efficacy of Givinostat in Patients With JAK2V617F Positive Polycythemia Vera
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 25 Sep 2017
At a glance
- Drugs Givinostat (Primary)
- Indications Polycythaemia vera
- Focus Adverse reactions; Therapeutic Use
- Sponsors Italfarmaco
- 20 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 01 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.